BCDA · Company research
BioCardia, Inc. Common Stock (BCDA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| BioCardia, Inc. (BCDA) Stock Price, News, Quote & History - Yahoo! Finance Canada | BioCardia, Inc. (BCDA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting | BioCardia announced the presentation of its CardiAMP HF II trial design at the HFSA Annual Scientific Meeting. The trial evaluates high-dose autologous cell therapy for patients with ischemic heart failure with reduced ejection fraction. The FDA has granted category B designation for the CardiAMP system and agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval. BioCardia is advancing regulatory submissions with the FDA and Japan's PMDA. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting | BioCardia announced the presentation of its CardiAMP HF II trial design at the HFSA Annual Scientific Meeting. The trial evaluates high-dose autologous cell therapy for patients with ischemic heart failure with reduced ejection fraction. The FDA has granted category B designation for the CardiAMP system and agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval. BioCardia is advancing regulatory submissions with the FDA and Japan's PMDA. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| FDA agrees BioCardia's heart-failure trial may support approval of its cell treatment. - Stock Titan | FDA agrees BioCardia's heart-failure trial may support approval of its cell treatment. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| FDA targets an initial review within 15 calendar days for a device that delivers therapy to the heart. - Stock Titan | FDA targets an initial review within 15 calendar days for a device that delivers therapy to the heart. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| A heart failure therapy is being prepared for Japan; PMDA support and a successful review could bring Q4 2027 clearance. - Stock Titan | A heart failure therapy is being prepared for Japan; PMDA support and a successful review could bring Q4 2027 clearance. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Insiders In BioCardia Still Down 21% On US$1.08m Investment - Simply Wall Street | Insiders In BioCardia Still Down 21% On US$1.08m Investment Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
| Should I buy BioCardia (BCDA) - Zacks Investment Research | Should I buy BioCardia (BCDA) Zacks Investment Research | View source ↗ | Zacks Investment Research | Jul 14, 2026 | neutral | 0 | 0.6 |
| BCDA Forecast — Price Target — Prediction for 2027 - TradingView | BCDA Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Insider Purchase: Director at $BCDA Buys 70,200 Shares | BCDA Stock News - Quiver Quantitative | Insider Purchase: Director at $BCDA Buys 70,200 Shares | BCDA Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 24, 2026 | neutral | 0 | 0.6 |
| BCDA Stock Surges As FDA Softens Trial Requirements For CardiAMP - Timothy Sykes | BCDA Stock Surges As FDA Softens Trial Requirements For CardiAMP Timothy Sykes | View source ↗ | Timothy Sykes | Jun 7, 2026 | neutral | 0 | 0.6 |
| Why Did BCDA Stock Surge More Than 50% Today? - Stocktwits | Why Did BCDA Stock Surge More Than 50% Today? Stocktwits | View source ↗ | Stocktwits | Jun 5, 2026 | neutral | 0 | 0.6 |
| $BCDA stock is up 51% today. Here's what we see in our data. - Quiver Quantitative | $BCDA stock is up 51% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 5, 2026 | neutral | 0 | 0.6 |
| BCDA Stock Holds Key Support As FDA Clears Paths For Helix - www.timothysykes.com | BCDA Stock Holds Key Support As FDA Clears Paths For Helix www.timothysykes.com | View source ↗ | www.timothysykes.com | Jun 5, 2026 | neutral | 0 | 0.6 |
| BCDA Stock Jumps As FDA Clears Path For Helix Catheter - StocksToTrade | BCDA Stock Jumps As FDA Clears Path For Helix Catheter StocksToTrade | View source ↗ | StocksToTrade | Jun 5, 2026 | neutral | 0 | 0.6 |
| BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) - Yahoo Finance | BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) Yahoo Finance | View source ↗ | Yahoo Finance | Jun 5, 2026 | neutral | 0 | 0.6 |
| BCDA - Finviz | BCDA Finviz | View source ↗ | Finviz | May 26, 2026 | neutral | 0 | 0.6 |
| BioCardia News: Why BCDA Stock Is Soaring Today - InvestorPlace | BioCardia News: Why BCDA Stock Is Soaring Today InvestorPlace | View source ↗ | InvestorPlace | Dec 18, 2020 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.